<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297865</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_JSI_101</org_study_id>
    <nct_id>NCT04297865</nct_id>
  </id_info>
  <brief_title>Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJ-15314 Phosphate in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJ-15314 Phosphate in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of
      CJ-15314 phosphate in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To evaluate the safety, tolerability and pharmacokinetics of single or multiple dose of
           CJ-15314 phosphate in healthy male subjects

        -  To explore the pharmacodynamics of single or multiple dose of CJ-15314 phosphate in
           healthy male subjects

        -  To explore the pharmacokinetics of CJ-15314 Phosphate active metabolites of single or
           multiple dose of CJ-15314 phosphate in healthy male subjects
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>λz of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vd/F of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fe of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLR of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin,ss of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cav,ss of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax,ss of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau,ss of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PTF of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ra of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fe of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLR of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratio of CJ-16118 (major metabolite of CJ-15314) of single dose of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cav,ss of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau,ss of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTF of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ra of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratio of CJ-16118 (major metabolite of CJ-15314) of multiple doses of CJ-15314</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A dose as CJ-15314 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of A as CJ-15314 or placebo once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B dose as CJ-15314 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of B as CJ-15314 or placebo once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C dose as CJ-15314 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of C as CJ-15314 or placebo once a day and once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D dose as CJ-15314 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of D as CJ-15314 or placebo once a day and once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E dose as CJ-15314 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of E as CJ-15314 or placebo once a day and once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F dose as CJ-15314 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of F as CJ-15314 or placebo once a day and once daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A dose as CJ-15314</intervention_name>
    <description>A dose as CJ-15314, 1 capsule</description>
    <arm_group_label>A dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B dose as CJ-15314</intervention_name>
    <description>B dose as CJ-15314, 1 capsule</description>
    <arm_group_label>B dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C dose as CJ-15314</intervention_name>
    <description>C dose as CJ-15314, 1 capsule</description>
    <arm_group_label>C dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D dose as CJ-15314</intervention_name>
    <description>D dose as CJ-15314, 2 capsules</description>
    <arm_group_label>D dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E dose as CJ-15314</intervention_name>
    <description>E dose as CJ-15314, 1 capsule</description>
    <arm_group_label>E dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F dose as CJ-15314</intervention_name>
    <description>F dose as CJ-15314, 2 capsules</description>
    <arm_group_label>F dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 1 capsule</description>
    <arm_group_label>A dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 1 capsule</description>
    <arm_group_label>B dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 1 capsule</description>
    <arm_group_label>C dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 2 capsules</description>
    <arm_group_label>D dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 1 capsule</description>
    <arm_group_label>E dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 2 capsules</description>
    <arm_group_label>F dose as CJ-15314 or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male adults aged 19 to 55 years (inclusive) at the time of signing the
             informed consent form.

          -  Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m^2 with a body weight ≥ 50.0 kg and ≤ 90.0
             kg at screening.

             ☞ BMI (kg/m^2) = weight (kg) / {height (m)}^2

          -  Decides to participate voluntarily in the study after being fully informed of and
             understanding the study completely, and provides his written informed consent prior to
             screening procedure.

          -  Determined eligible for this study in the opinion of the investigator based on the
             results of vital signs, physical examination, 12-lead electrocardiogram, clinical
             laboratory tests, and medical interview drug screening test.

        Exclusion Criteria:

          -  Has a history or current evidence of clinically significant disorder of hepatic,
             renal, nervous, respiratory, endocrine, hemato-oncologic, cardiovascular, urinary,
             and/or psychiatric system.

          -  Has a history or current evidence of gastrointestinal disease that may affect the
             safety and PD assessment of IP or a history of gastrointestinal surgery (except for
             simple appendectomy or herniotomy).

          -  Has rheumatoid arthritis or has a history.

          -  Has symptomatic herpes simplex or herpes zoster or has a history within 3 months prior
             to the scheduled first dose.

          -  Has live vaccine dose within 3 months prior to the scheduled first dose or expects to
             receive live vaccine during the clinical trial period.

          -  Has a history or current evidence of clinically significant hypersensitivity to drugs
             containing any ingredient of Janus kinase inhibitor and other drugs.

          -  Has a positive result on serology tests (for hepatitis B, hepatitis C and human
             immunodeficiency virus [HIV]) during screening test.

          -  Has abnormalities one or more of the following during screening test: AST [GOT] or ALT
             [GPT] &gt; 1.5 X upper limit of normal (ULN), Creatinine &gt; upper limit of normal (ULN),
             ANC &lt; 2,000/uL, Hb &lt;12.5 g/dL, Platelet &lt; 150,000/uL, QTc interval at 12-lead
             electrocardiogram &gt; 450 msec

          -  Systolic blood pressure (SBP) &lt; 90 mmHg or &gt; 140 mmHg, diastolic blood pressure (DBP)
             &lt; 50 mmHg or &gt; 95 mm Hg, or pulse rate (PR) &lt; 45 beats/min or &gt; 100 beats/min on vital
             signs measured in sitting position after taking a rest for at least 5 minutes during
             screening test.

          -  Has a history of drug abuse or has a positive response to drug abuse on urine drug
             screening test.

          -  Has taken any prescription drugs or herbal medicine within 2 weeks prior to the
             expected date of first dose, or has taken or is expected to take any over-the-counter
             (OTC) drug, health functional food or vitamin preparation within 1 week prior to the
             expected date of the first dose (However, can participate in the study if otherwise
             eligible in the judgment of the investigator).

          -  Has participated in any other clinical study or bioequivalence study and received IPs
             within 6 months prior to the scheduled first dose.

          -  Has donated whole blood within 2 months prior to the scheduled first dose, or has
             donated blood components or received transfusion within a month prior to the scheduled
             first dose.

          -  Has a history of excessive smoking (&gt; 10 cigarettes/day) within 3 months prior to the
             scheduled first dose or confirmed as positive for cotinine on urine drug screening
             test.

          -  Excessive caffeine intake (&gt; 5 units/day), continued use of alcohol (&gt; 21 units/week,
             1 unit = 10 g of pure alcohol), or unable to stop drinking during hospitalization
             period.

          -  Unable to avoid caffeine-containing foods (e.g., coffee, tea [black tea, green tea,
             etc.], soda, coffee-flavored milk, and nutritive tonic drink) during the period from
             24 hrs before hospitalization to discharge.

          -  Unable to use a medically acceptable contraceptive method throughout the study.

             ► Medically acceptable contraceptive methods include:

               1. Use of intrauterine device with a proven birth control failure rate by the spouse
                  (or partner)

               2. Simultaneous use of (male or female) barrier method and spermicide

               3. Surgical sterilization of the subject or his partner (e.g., vasectomy,
                  salpingectomy, tubal ligation, or hysterectomy)

          -  Determined ineligible for study participation by the investigator for other reasons
             such as clinical laboratory abnormalities.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hukeun Lee, MS</last_name>
    <phone>+82-2-6477-0208</phone>
    <email>hukeun.lee@kolmar.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seokuee Kim, MD, PhD</last_name>
    <phone>+82-2-6477-0207</phone>
    <email>seokuee.kim@kolmar.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital, Dept. of Clinical Pharmacology</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Jin Jang, MD, PhD</last_name>
      <phone>82-2-2072-1666</phone>
      <email>ijjang@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

